Study from Cleveland Clinic shows 81.8% lower reinfection rates among those who had prior COVID-19. Those who got reinfection were all mild or asymptomatic. The degree of protection seemed to improve with time.
150,435 people were studied. Of these, 8845 had prior COVID-19. In this group, 62 cases of reinfection occurred. That is 0.7%. Half were asymptomatic. None were severe or needed ICU care. No deaths.
2/7
141480 people did not have a history of COVID-19. Among this group, 5449 got COVID-19 during the same time period. That is 3.85%. 60% were symptomatic. No severe cases.
3/7
The calculated difference between infection rates in the 2 groups was 0.7% vs. 3.85% = 81.8%
Not only is there a difference in infection rates between the 2 groups, the testing rates in the past infection group was only half (14%) compared to no prior infection group (28%)
4/7
The chance of a test becoming positive in the prior infection group was only 5%, while it was 14% among those who never had infection previously.
The criteria for testing are not clear, the paper says 40% were done for screening purposes in the second group.
5/7
Hence, it is not exactly an apple to apple comparison. Were people left out of testing as they had prior infection? Did they fail to report symptoms which the second group would have brought to medical attention? Did those who past infection ignore precautions?
6/7
In summary, the available information from this large database from a healthcare system indicates an 81.8% difference between the apparent infection rates in the 2 groups, which may be interpreted as 'protection' due to prior infection. This correlates with other studies.
7/7
• • •
Missing some Tweet in this thread? You can try to
force a refresh
“Landmark Scottish study suggests children may protect adults from Covid”
Misleading “click bait” conclusions such as this are common when looking at data without understanding the multitude of interconnected factors involved.
The study claims that the more the number of children in a household, the lower the risk of hospitalisation is. While this is an interesting observation, we need to look at the variables involved.
2/8
Those households with children have younger adults as parents, hence less likely to get severe COVID-19.
Their social behaviour trends will be different to those who are single or couples without children. For instance they might eat out less or go to pubs less frequently.
3/8
The South Africa trial on Astra Oxford vaccine (against B1.351 variant) was based on a tiny number of people, with unacceptably wide confidence intervals (-50 to +60) which by definition means “too small a sample size”, and the “true value” could lie anywhere in that range.
They looked at just 714 who got placebo, and who 750 got vaccine. Out of these, only 42 people got COVID-19, of whom 32 were mild. With only 10 moderate cases and zero severe cases, it is impossible to conclude anything about the vaccine’s efficacy.
2/4
The aim of COVID-19 vaccination is to prevent severe disease. Without any severe disease in either placebo or vaccine arm, this trial is best called inconclusive. By definition, it can be concluded that “the study needs to be replicated using a sufficiently large sample size”
3/4
The exact cause of these deaths is not known. But when events like this occur in someone who received vaccine, it gets the attention of the world.
Young deaths (non violent) occur from many reasons.
e.g. undetected cardiac illness, cerebral aneurysms, liver disease (see pic)
Italy is going through a COVID-19 surge now, which is bigger than April 2020. Silent or undiagnosed infections could result in deaths from vascular thrombosis that could be interpreted as sudden unexplained deaths. Such events occur even after recovery.
UK study shows GM-CSF is elevated early in those who will go on to get severe COVID-19. Other markers such as IL-2, IL-6 & D-Dimer also predict a severe course.
GM-CSF recruits monocytes and neutrophils into lungs, causing inflammation and damage.
The authors report that GM-CSF elevation is a feature of fatal COVID-19 (elevated 9.7 times), compared to fatal influenza (elevated only 1.4 times).
Older people and those with heart disease or diabetes had such elevations, but these conditions also correlate with age.
2/4
Interpreting such findings is not easy and is prone to error. Immunology involves the simultaneous and sequential action of numerous players, many of whom have a positive and negative feedback role.
The GM-CSF is part of a chain of events in a dysregulated immune response.
3/4
EMA (European Medicines Agency) clears Astra-Oxford Vaccine
"The problems that have arisen in Austria in individuals after receiving AstraZeneca's corona vaccine were not caused by that vaccine"
-conclusion of European regulator for vaccines and medicines, EMA.
1/3
"A 49-year-old woman in Austria died of severe blood clotting. Ten days earlier she had received the corona vaccine from AstraZeneca. A 35-year-old woman developed a pulmonary embolism from which she is now recovering"
"There were 2 more similar incidents. According to the EMA, this is not exceptional, it corresponds to the number of incidents among the general population. In Europe, 3 million people have been vaccinated with AstraZeneca, and 22 of them have had thrombosis or embolism"
3/4
“The National Board of Health Denmark is now awaiting the EU drug authorities to investigate the possible connection between the COVID-19 vaccine from AstraZeneca and the serious cases of blood clots that have been reported”
“In six other European countries, the use of a specific batch of the AstraZeneca vaccine has currently been suspended pending investigations.
Unit Manager Tanja Erichsen encourages you to take it easy if you have been vaccinated with AstraZeneca's vaccine”
"I understand well if you are worried, but you must keep in mind that no connection has yet been established between the vaccines from AstraZeneca and the cases of blood clots. That is what we now want to investigate”